(IN BRIEF) Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant. The approval is based on positive results from … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Approval, cancer treatment, CHINA, clinical trials, EU, FDA, global health, IMROZ study, isatuximab, Japan, Multiple Myeloma, Multiple Myeloma Treatment, new approvals, NMPA, oncology, Sanofi, Sarclisa, transplant-ineligible, VRd
(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least one prior therapy. The approval is based on the … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anti-CD38 antibody, autologous stem cell transplant, bortezomib, CACA, Category I Recommendation, Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology, clinical data, CSCO, dexamethasone, Global Head of Oncology, ICARIA-MM phase 3 study, innovative regulatory pathways, innovative therapies, IsaFiRsT real-world study, Lecheng Pilot Program, lenalidomide, local authorities, medical community, National Medical Products Administration, newly diagnosed multiple myeloma, NMPA, Olivier Nataf, overall response rate, overall survival, Pd, pomalidomide, R/R MM, real-world evidence, regulatory submission, relapsed or refractory multiple myeloma, RWE, Sanofi, Sanofi in China, Sarclisa
HILDEN, Deutschland, GERMANTOWN, Maryland (USA), und SHANGHAI, China, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA), ein deutscher Anbieter von Sample-to-Insights-Lösungen, die es Kunden ermöglichen, Einblicke in die Bausteine des Lebens – DNA, RNA und Proteine … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON Tuberkulose, QuantiFERON-TB Gold Plus, TB-Bakterien, TB-Diagnose, TB-Infektionen, TB-Tests, TST, Tuberkulin-Hauttest, UNITAID, Weltgesundheitsorganisation, WHO
(COMMUNIQUÉ DE PRESSE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE : QGEN ; Frankfurt Prime Standard : QIA), une société allemande fournisseur de solutions Sample to Insights qui permettent aux clients de débloquer des informations sur … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Académie chinoise des sciences médicales, bactérie de la tuberculose, dépistage de la tuberculose, diagnostic de la tuberculose, Dr. Gao Lei, IGR, infections tuberculeuses, Jean-Pascal Viola, NMPA, OMS, Organisation mondiale de la santé, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB® Gold Plus, test cutané à la tuberculine, TST, UNITAID
(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a German provider of Sample to Insights solutions that enable customers to unlock insights from the building … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN N.V., QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB Gold Plus, TB bacteria, TB diagnosis, TB infections, TB testing, TST, Tuberculin Skin Test, UNITAID, WHO, World Health Organization
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?